- •Hematuria II: causes and investigation
- •Hematospermia
- •Lower urinary tract symptoms (LUTS)
- •Nocturia and nocturnal polyuria
- •Flank pain
- •Urinary incontinence in adults
- •Genital symptoms
- •Abdominal examination in urological disease
- •Digital rectal examination (DRE)
- •Lumps in the groin
- •Lumps in the scrotum
- •2 Urological investigations
- •Urine examination
- •Urine cytology
- •Radiological imaging of the urinary tract
- •Uses of plain abdominal radiography (KUB X-ray—kidneys, ureters, bladder)
- •Intravenous pyelography (IVP)
- •Other urological contrast studies
- •Computed tomography (CT) and magnetic resonance imaging (MRI)
- •Radioisotope imaging
- •Post-void residual urine volume measurement
- •3 Bladder outlet obstruction
- •Regulation of prostate growth and development of benign prostatic hyperplasia (BPH)
- •Pathophysiology and causes of bladder outlet obstruction (BOO) and BPH
- •Benign prostatic obstruction (BPO): symptoms and signs
- •Diagnostic tests in men with LUTS thought to be due to BPH
- •Why do men seek treatment for their symptoms?
- •Watchful waiting for uncomplicated BPH
- •Medical management of BPH: combination therapy
- •Medical management of BPH: alternative drug therapy
- •Minimally invasive management of BPH: surgical alternatives to TURP
- •Invasive surgical alternatives to TURP
- •TURP and open prostatectomy
- •Indications for and technique of urethral catheterization
- •Indications for and technique of suprapubic catheterization
- •Management of nocturia and nocturnal polyuria
- •High-pressure chronic retention (HPCR)
- •Bladder outlet obstruction and retention in women
- •Urethral stricture disease
- •4 Incontinence
- •Causes and pathophysiology
- •Evaluation
- •Treatment of sphincter weakness incontinence: injection therapy
- •Treatment of sphincter weakness incontinence: retropubic suspension
- •Treatment of sphincter weakness incontinence: pubovaginal slings
- •Overactive bladder: conventional treatment
- •Overactive bladder: options for failed conventional therapy
- •“Mixed” incontinence
- •Post-prostatectomy incontinence
- •Incontinence in the elderly patient
- •Urinary tract infection: microbiology
- •Lower urinary tract infection
- •Recurrent urinary tract infection
- •Urinary tract infection: treatment
- •Acute pyelonephritis
- •Pyonephrosis and perinephric abscess
- •Other forms of pyelonephritis
- •Chronic pyelonephritis
- •Septicemia and urosepsis
- •Fournier gangrene
- •Epididymitis and orchitis
- •Periurethral abscess
- •Prostatitis: presentation, evaluation, and treatment
- •Other prostate infections
- •Interstitial cystitis
- •Tuberculosis
- •Parasitic infections
- •HIV in urological surgery
- •6 Urological neoplasia
- •Pathology and molecular biology
- •Prostate cancer: epidemiology and etiology
- •Prostate cancer: incidence, prevalence, and mortality
- •Prostate cancer pathology: premalignant lesions
- •Counseling before prostate cancer screening
- •Prostate cancer: clinical presentation
- •PSA and prostate cancer
- •PSA derivatives: free-to-total ratio, density, and velocity
- •Prostate cancer: transrectal ultrasonography and biopsies
- •Prostate cancer staging
- •Prostate cancer grading
- •General principles of management of localized prostate cancer
- •Management of localized prostate cancer: watchful waiting and active surveillance
- •Management of localized prostate cancer: radical prostatectomy
- •Postoperative course after radical prostatectomy
- •Prostate cancer control with radical prostatectomy
- •Management of localized prostate cancer: radical external beam radiotherapy (EBRT)
- •Management of localized prostate cancer: brachytherapy (BT)
- •Management of localized and radiorecurrent prostate cancer: cryotherapy and HIFU
- •Management of locally advanced nonmetastatic prostate cancer (T3–4 N0M0)
- •Management of advanced prostate cancer: hormone therapy I
- •Management of advanced prostate cancer: hormone therapy II
- •Management of advanced prostate cancer: hormone therapy III
- •Management of advanced prostate cancer: androgen-independent/ castration-resistant disease
- •Palliative management of prostate cancer
- •Prostate cancer: prevention; complementary and alternative therapies
- •Bladder cancer: epidemiology and etiology
- •Bladder cancer: pathology and staging
- •Bladder cancer: presentation
- •Bladder cancer: diagnosis and staging
- •Muscle-invasive bladder cancer: surgical management of localized (pT2/3a) disease
- •Muscle-invasive bladder cancer: radical and palliative radiotherapy
- •Muscle-invasive bladder cancer: management of locally advanced and metastatic disease
- •Bladder cancer: urinary diversion after cystectomy
- •Transitional cell carcinoma (UC) of the renal pelvis and ureter
- •Radiological assessment of renal masses
- •Benign renal masses
- •Renal cell carcinoma: epidemiology and etiology
- •Renal cell carcinoma: pathology, staging, and prognosis
- •Renal cell carcinoma: presentation and investigations
- •Renal cell carcinoma: active surveillance
- •Renal cell carcinoma: surgical treatment I
- •Renal cell carcinoma: surgical treatment II
- •Renal cell carcinoma: management of metastatic disease
- •Testicular cancer: epidemiology and etiology
- •Testicular cancer: clinical presentation
- •Testicular cancer: serum markers
- •Testicular cancer: pathology and staging
- •Testicular cancer: prognostic staging system for metastatic germ cell cancer
- •Testicular cancer: management of non-seminomatous germ cell tumors (NSGCT)
- •Testicular cancer: management of seminoma, IGCN, and lymphoma
- •Penile neoplasia: benign, viral-related, and premalignant lesions
- •Penile cancer: epidemiology, risk factors, and pathology
- •Squamous cell carcinoma of the penis: clinical management
- •Carcinoma of the scrotum
- •Tumors of the testicular adnexa
- •Urethral cancer
- •Wilms tumor and neuroblastoma
- •7 Miscellaneous urological diseases of the kidney
- •Cystic renal disease: simple cysts
- •Cystic renal disease: calyceal diverticulum
- •Cystic renal disease: medullary sponge kidney (MSK)
- •Acquired renal cystic disease (ARCD)
- •Autosomal dominant (adult) polycystic kidney disease (ADPKD)
- •Ureteropelvic junction (UPJ) obstruction in adults
- •Anomalies of renal ascent and fusion: horseshoe kidney, pelvic kidney, malrotation
- •Renal duplications
- •8 Stone disease
- •Kidney stones: epidemiology
- •Kidney stones: types and predisposing factors
- •Kidney stones: mechanisms of formation
- •Evaluation of the stone former
- •Kidney stones: presentation and diagnosis
- •Kidney stone treatment options: watchful waiting
- •Stone fragmentation techniques: extracorporeal lithotripsy (ESWL)
- •Intracorporeal techniques of stone fragmentation (fragmentation within the body)
- •Kidney stone treatment: percutaneous nephrolithotomy (PCNL)
- •Kidney stones: open stone surgery
- •Kidney stones: medical therapy (dissolution therapy)
- •Ureteric stones: presentation
- •Ureteric stones: diagnostic radiological imaging
- •Ureteric stones: acute management
- •Ureteric stones: indications for intervention to relieve obstruction and/or remove the stone
- •Ureteric stone treatment
- •Treatment options for ureteric stones
- •Prevention of calcium oxalate stone formation
- •Bladder stones
- •Management of ureteric stones in pregnancy
- •Hydronephrosis
- •Management of ureteric strictures (other than UPJ obstruction)
- •Pathophysiology of urinary tract obstruction
- •Ureter innervation
- •10 Trauma to the urinary tract and other urological emergencies
- •Renal trauma: clinical and radiological assessment
- •Renal trauma: treatment
- •Ureteral injuries: mechanisms and diagnosis
- •Ureteral injuries: management
- •Bladder and urethral injuries associated with pelvic fractures
- •Bladder injuries
- •Posterior urethral injuries in males and urethral injuries in females
- •Anterior urethral injuries
- •Testicular injuries
- •Penile injuries
- •Torsion of the testis and testicular appendages
- •Paraphimosis
- •Malignant ureteral obstruction
- •Spinal cord and cauda equina compression
- •11 Infertility
- •Male reproductive physiology
- •Etiology and evaluation of male infertility
- •Lab investigation of male infertility
- •Oligospermia and azoospermia
- •Varicocele
- •Treatment options for male factor infertility
- •12 Disorders of erectile function, ejaculation, and seminal vesicles
- •Physiology of erection and ejaculation
- •Impotence: evaluation
- •Impotence: treatment
- •Retrograde ejaculation
- •Peyronie’s disease
- •Priapism
- •13 Neuropathic bladder
- •Innervation of the lower urinary tract (LUT)
- •Physiology of urine storage and micturition
- •Bladder and sphincter behavior in the patient with neurological disease
- •The neuropathic lower urinary tract: clinical consequences of storage and emptying problems
- •Bladder management techniques for the neuropathic patient
- •Catheters and sheaths and the neuropathic patient
- •Management of incontinence in the neuropathic patient
- •Management of recurrent urinary tract infections (UTIs) in the neuropathic patient
- •Management of hydronephrosis in the neuropathic patient
- •Bladder dysfunction in multiple sclerosis, in Parkinson disease, after stroke, and in other neurological disease
- •Neuromodulation in lower urinary tract dysfunction
- •14 Urological problems in pregnancy
- •Physiological and anatomical changes in the urinary tract
- •Urinary tract infection (UTI)
- •Hydronephrosis
- •15 Pediatric urology
- •Embryology: urinary tract
- •Undescended testes
- •Urinary tract infection (UTI)
- •Ectopic ureter
- •Ureterocele
- •Ureteropelvic junction (UPJ) obstruction
- •Hypospadias
- •Normal sexual differentiation
- •Abnormal sexual differentiation
- •Cystic kidney disease
- •Exstrophy
- •Epispadias
- •Posterior urethral valves
- •Non-neurogenic voiding dysfunction
- •Nocturnal enuresis
- •16 Urological surgery and equipment
- •Preparation of the patient for urological surgery
- •Antibiotic prophylaxis in urological surgery
- •Complications of surgery in general: DVT and PE
- •Fluid balance and management of shock in the surgical patient
- •Patient safety in the operating room
- •Transurethral resection (TUR) syndrome
- •Catheters and drains in urological surgery
- •Guide wires
- •JJ stents
- •Lasers in urological surgery
- •Diathermy
- •Sterilization of urological equipment
- •Telescopes and light sources in urological endoscopy
- •Consent: general principles
- •Cystoscopy
- •Transurethral resection of the prostate (TURP)
- •Transurethral resection of bladder tumor (TURBT)
- •Optical urethrotomy
- •Circumcision
- •Hydrocele and epididymal cyst removal
- •Nesbit procedure
- •Vasectomy and vasovasostomy
- •Orchiectomy
- •Urological incisions
- •JJ stent insertion
- •Nephrectomy and nephroureterectomy
- •Radical prostatectomy
- •Radical cystectomy
- •Ileal conduit
- •Percutaneous nephrolithotomy (PCNL)
- •Ureteroscopes and ureteroscopy
- •Pyeloplasty
- •Laparoscopic surgery
- •Endoscopic cystolitholapaxy and (open) cystolithotomy
- •Scrotal exploration for torsion and orchiopexy
- •17 Basic science of relevance to urological practice
- •Physiology of bladder and urethra
- •Renal anatomy: renal blood flow and renal function
- •Renal physiology: regulation of water balance
- •Renal physiology: regulation of sodium and potassium excretion
- •Renal physiology: acid–base balance
- •18 Urological eponyms
- •Index
366 CHAPTER 8 Stone disease
Evaluation of the stone former
Determination of stone type and a metabolic evaluation allows identification of the factors that led to stone formation, so advice can be given to prevent future stone formation.
Metabolic evaluation depends, to an extent, on the stone type (see Table 8.2). In many cases a stone is retrieved. Stone type is analyzed by polarizing microscopy, X-ray diffraction, and infrared spectroscopy, rather than by chemical analysis. Where no stone is retrieved, its nature must be inferred from its radiological appearance (e.g., a completely radiolucent stone is likely to be composed of uric acid) or from more detailed metabolic evaluation.
In most patients, multiple factors are involved in the genesis of kidney stones and, as a general guide, the following evaluation is appropriate in most patients.
Risk factors for stone disease
-Diet: Enquire about volume of fluid intake, meat consumption (causes hypercalciuria, high uric acid levels, low urine pH, low urinary citrate), multivitamins (vitamin D increases intestinal calcium absorption), high doses of vitamin C (ascorbic acid causes hyperoxaluria).
-Drugs: Corticosteroids (increase enteric absorption of calcium, leading to hypercalciuria); chemotherapeutic agents (breakdown products of malignant cells leads to hyperuricemia).
-Urinary tract infection: Urease-producing bacteria (Proteus, Klebsiella, Serratia, Enterobacter) predispose to struvite stones.
-Mobility: Low activity levels predispose to bone demineralization and hypercalciuria.
-Systemic disease: gout, primary hyperparathyroidism, sarcoidosis
-Family history: cystinuria, RTA
-Renal anatomy: UPJ, horseshoe kidney, medullary sponge kidney (up to 2% of patients with calcium-containing stones have MSK)
-Previous bowel resection or inflammatory bowel disease causes intestinal hyperoxaluria.
Metabolic evaluation of the stone former
Patients can be categorized as low risk or high risk for subsequent stone formation. High risk includes previous history of a stone, family history of stones, gastrointestinal (GI) disease, gout, chronic UTI, nephrocalcinosis.
Low-risk patient evaluation
Assess urea and electrolytes, CBC (to detect undiagnosed hematological malignancy), serum calcium (corrected for serum albumin), and uric acid, as well as urine culture, and urine dipstick for pH (see below).
High-risk patient evaluation
Evaluation is the same as for low-risk patients plus 24-hour urine for calcium, oxalate, uric acid, and cystine, and evaluation for RTA.
EVALUATION OF THE STONE FORMER 367
Table 8.2 Characteristics of stone types
Stone type |
Urine acidity |
Mean urine pH (SEM) |
Calcium oxalate |
Variable |
6 (± 0.4) |
Calcium phosphate |
Tendency toward alkaline urine |
>5.5 |
Uric acid |
Acid |
5.5 (± 0.4) |
Struvite |
Alkaline* |
— |
Cystine |
Normal (5–7) |
— |
|
|
|
* Urine pH must be above 7.2 for deposition of struvite crystals.
Urine pH
Urine pH in normal individuals shows variation, pH 5–7. After a meal, pH is initially acid because of acid production from metabolism of purines (nucleic acids in, for example, meat). This is followed by an alkaline tide, with pH rising to >6.5.
Urine pH can help establish what type of stone the patient may have (if a stone is not available for analysis) and can help the urologist and patient in determining whether preventative measures are likely to be effective or not.
•pH <6 in a patient with radiolucent stones suggests the presence of uric acid stones.
•pH consistently >5.5 suggests type 1 (distal) RTA (~70% of such patients will form calcium phosphate stones).
Evaluation for RTA
Evaluate for RTA if there are calcium phosphate stones, bilateral stones, nephrocalcinosis, MSK, or hypocitraturia.
-If fasting morning urine pH (i.e., first urine of the day) is >5.5, the patient has complete distal RTA.
-First and second morning urine pH is a useful screening test for detection of incomplete distal RTA; over 90% of cases of RTA have a pH >6 on both specimens. The ammonium chloride loading test involves an oral dose of ammonium chloride (0.1 g/kg; an acid load). If serum pH falls <7.3 or serum bicarbonate falls <16 mmol/L, but urine pH remains >5.5, the patient has incomplete distal RTA.
Diagnostic tests for suspected cystinuria
These include the cyanide-nitroprusside colorimetric test (cystine spot test). If positive, a 24-hour urine collection is done. A 24-hour cystine >250 mg is diagnostic of cystinuria.1
1 Millman S, Strauss AL, Parks JH, Coe FL (1982). Pathogenesis and clinical course of mixed calcium oxalate and uric acid nephrolithiasis. Kidney Int 22:366–370.
368 CHAPTER 8 Stone disease
Kidney stones: presentation and diagnosis
Kidney stones may present with symptoms or be found incidentally during investigation of other problems. Presenting symptoms include pain or hematuria (microscopic or occasionally macroscopic). Struvite staghorn calculi classically present with recurrent UTIs. Malaise, weakness, and loss of appetite can also occur.
Less commonly, struvite stones present with infective complications (pyonephrosis, perinephric abscess, septicemia, xanthogranulomatous pyelonephritis).
Diagnostic tests
-Plain abdominal radiography: Calculi that contain calcium are radiodense. Sulfur-containing stones (cystine) are relatively radiolucent on plain radiography.
-Radiodensity of stones in decreasing order is calcium phosphate > calcium oxalate > struvite (magnesium ammonium phosphate) >> cystine.
-Completely radiolucent stones (e.g., uric acid, triamterene, indinavir) are usually suspected on the basis of the patient’s history and/or urine pH (pH <6: gout; drug history: triamterene, indinavir), and the diagnosis may be confirmed by ultrasound, computed tomographic urography (CTU), or magnetic resonance urography (MRU).
-Renal ultrasound: Its sensitivity for detecting renal calculi is ~95%.1
A combination of plain abdominal radiography and renal ultrasonography is a useful screening test for renal calculi.
-IVP is increasingly being replaced by CTU. IVP is useful for patients with suspected indinavir stones (which are not visible on CT).
-CTU is a very accurate method of diagnosing all but indinavir stones. It allows accurate determination of stone size and location and good definition of pelvicalyceal anatomy.
-MRU cannot visualize stones but is able to demonstrate the presence of hydronephrosis.
1 Haddad MC, Sharif HS, Abomelha ME, et al. (1992) Management of renal colic: redefining the role of the urogram. Radiology 184:35–36.
This page intentionally left blank